Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Goldschmidt, Hartmut

Oral and Poster Abstracts
Oral
654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma

Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Study Population, Human

Hartmut Goldschmidt, MD^1,2, Uta Bertsch, MD^3,4^*, Ema Pozek⁵^*, Axel Benner⁶^*, Roland Fenk, MD, PhD⁷^*, Britta Besemer, MD⁸^*, Christine Hanoun⁹^*, Roland Schroers, MD¹⁰^*, Ivana von Metzler, MD¹¹^*, Mathias Hänel, MD¹², Christoph Mann, MD¹³^*, Lisa Leypoldt, MD¹⁴^*, Bernhard Heilmeier¹⁵^*, Stefanie Huhn, PhD¹⁶^*, Sabine Vogel, PhD¹⁷^*, Michael Hundemer, MD¹⁸^*, Christof Scheid, MD¹⁹, Igor Wolfgang Blau, MD, PhD²⁰^*, Steffen Luntz, MD²¹^*, Tobias A.W. Holderried, MD²²^*, Karolin Trautmann-Grill²³^*, Deniz Gezer, MD²⁴^*, Maika Klaiber-Hakimi²⁵^*, Martin Mueller, MD²⁶^*, Evgenii Shumilov²⁷^*, Wolfgang Knauf, MD²⁸^*, Christian Sebastian Michel, MD²⁹^*, Thomas Geer, MD³⁰, Hendrik Riesenberg³¹^*, Christoph Lutz³²^*, Marc-Steffen Raab³³^*, Martin Hoffmann³⁴^*, Katja C. Weisel, MD³⁵, Hans Salwender, MD³⁶^* and Elias K. Mai, MD³⁷^*

¹Internal Medicine V, GMMG - Study Group at University Hospital Heidelberg, Heidelberg, Germany
²National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany
³National Center for Tumor Diseases Heidelberg, Heidelberg, Germany
⁴Internal Medicine V, Hematology, Oncology and Rheumatology, GMMG Studygroup, Heidelberg University Hospital, Heidelberg, Germany
⁵German Cancer Research Center, Heidelberg, DEU
⁶Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
⁷Department of Haematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany
⁸Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany
⁹Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
¹⁰Knappschaftskrankenhaus Bochum, University Hospital Bochum, Bochum, Germany
¹¹Department of Medicine II – Hematology and Oncology, Goethe-University Frankfurt, University Hospital, Frankfurt am Main, Germany
¹²Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany
¹³Department of Haematology, Oncology and Immunology, Philipps-University Marburg, Marburg, Germany
¹⁴University Medical Center Hamburg Eppendorf, Hamburg, Germany
¹⁵Clinic for Oncology and Hematology, Hospital Barmherzige Brueder Regensburg, Regensburg, Germany, Regensburg, DEU
¹⁶Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
¹⁷Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany, Heidelberg, Germany
¹⁸Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
¹⁹Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany
²⁰Medical Clinic, Charité University Medicine Berlin, Berlin, Germany
²¹Coordination Centre for Clinical Trials (KKS), Heidelberg, Germany
²²Department of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, University Hospital Bonn, Bonn, Germany
²³University Hospital Carl Gustav Carus, Dresden, Germany
²⁴Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, DEU
²⁵Clinic for Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany, Duesseldorf, DEU
²⁶Klinikum Siloah Hannover, Hannover, Germany, Hannover, AL, DEU
²⁷Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
²⁸Center for Hematology and Oncology, Bethanien, Frankfurt a.M., Germany, Frankfurt a.M., Germany
²⁹Department of Internal Medicine III, University Hospital Mainz, Mainz, Germany
³⁰Medizinische Klinik Schwäbisch-Hall, Schwabisch Hall, DEU
³¹Hematology / Oncology Center, Bielefeld, Germany, Bielefeld, Germany
³²Hematology / Oncology Center, Koblenz, Germany, Koblenz, Germany
³³Department of Medicine V, Heidelberg Myeloma Center, University Hospital Heidelberg, Heidelberg, Germany
³⁴Medical Clinic A, Clinic Ludwigshafen, Ludwigshafen, Germany, Ludwigshafen, Germany
³⁵Department of Oncology, Hematology and BMT, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
³⁶Asklepios Tumorzentrum Hamburg, Asklepios Hospital Hamburg Altona and St. Georg, Hamburg, Germany
³⁷Heidelberg Myeloma Center, Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany

Background: In patients (pts) with newly diagnosed multiple myeloma (NDMM), anti-CD38 monoclonal antibodies (CD38-mAb) increase efficacy of standard-of-care regimens. Addition of the CD38-mAb isatuximab (Isa) to lenalidomide, bortezomib, and dexamethasone (RVd) in pts with transplant-eligible NDMM met the primary endpoint of minimal residual disease (MRD) negativity in the bone marrow after induction therapy (Isa-RVd 50% vs. RVd 36%, OR 1.82, 95% CI 1.33-2.48, p<0.001; Goldschmidt H et al., 2022, Lancet Haematol.; NCT03617731). The present analysis compared the effect of induction therapy with Isa-RVd vs. RVd on secondary endpoint of progression-free survival (PFS).

Methods: Pts with transplant-eligible NDMM at 67 sites in Germany were stratified by Revised International Staging System (R-ISS; Palumbo A et al., 2015, J Clin Oncol) and equally randomized to receive three 42-day cycles of RVd (lenalidomide 25 mg/d po, d1-14 and d22-35; bortezomib 1.3 mg/m² SC d1, 4, 8, 11, 22, 25, 29, 32; dexamethasone 20 mg/d po, d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33). In the Isa-RVd arm, Isa was added as follows: 10 mg/kg IV, cycle 1: d 1, 8, 15, 22, 29; cycles 2-3: d 1, 15, 29. Following induction therapy, pts underwent cyclophosphamide-based stem cell collection and subsequently proceeded to high-dose melphalan (200 mg/m²) and autologous hematopoietic stem cell transplant (ASCT). Second ASCT was recommended if pts achieved less than complete response (CR) after first ASCT or in case of high-risk cytogenetics. Pts were then randomized to receive maintenance with either lenalidomide alone (10 mg/d po continuously) or in combination with Isa (10 mg/kg IV, cycle 1: d 1, 8, 15, 22; cycles 2-3: d 1, 15; cycles 4-39: d 1) for up to 36 months. Cytogenetic risk status was defined as presence (high-risk) or absence (standard risk) of deletion17p, t(4;14), and/or t(14;16). PFS was defined as time from first randomization to progression or death from any cause, whichever occurred first. Weighted risk set estimator analyses accounting for second randomization (maintenance therapy) were applied to analyze PFS comparing Isa-RVd with RVd induction followed by lenalidomide maintenance. Data cut-off for the present analysis was January 31, 2024.

Results: Between Oct 2018 and Sep 2020, 662 pts were included in the trial. The intention-to-treat analysis comprised 660 pts (Isa-RVd: 331 and RVd: 329). Baseline characteristics were well balanced. 225 (68%)/79 (24%) pts in the Isa-RVd arm and 179 (54%)/99 (30%) pts in the RVd arm received a single or tandem ASCT, respectively.

After a median follow up of 47 months (95% CI 46-48), 179 PFS events occurred. Isa-RVd induction therapy significantly prolonged PFS compared with RVd (HR 0.70, 95% CI 0.52-0.94; stratified log-rank p=0.0184). 3-year PFS rates in the Isa-RVd and RVd arms were 83% (95% CI 79-87) and 75% (95% CI 70-80). The PFS benefit for Isa-RVd vs. RVd arm was confirmed on multivariable analysis, including R-ISS, age, sex, performance status, and renal insufficiency (HR 0.64, 95% CI 0.47-0.86; p=0.004). Subgroup analyses found a consistent PFS benefit for Isa-RVd vs. RVd induction among clinically relevant baseline subgroups (female and male sex, good performance status, ISS stages I, II, and III, normal and elevated LDH, standard risk cytogenetics). Patients with poor performance status (WHO grade >1, HR 1.09, 95% CI 0.47-2.52), and high-risk cytogenetics (HR 1.09, 95% CI 0.63-1.91) did not see benefit at this point.

Weighted risk set estimator PFS analyses accounting for second randomization confirmed a significant benefit for Isa-RVd vs. RVd induction followed by lenalidomide maintenance (HR 0.63, 95% CI 0.38-1.07; stratified weighted log-rank p=0.016). Estimated, weighted 3-year PFS rates for Isa-RVd and RVd followed by lenalidomide maintenance were 84% (95% CI 79-89) and 73% (95% CI 67-79).

OS was not mature with median OS not reached in either arm, and 3-year OS rates of 88% (95% CI 85-92) and 89% (95% CI 86-93) in the Isa-RVd vs. RVd arm.

Conclusions: Addition of Isa to RVd during 18 weeks of induction therapy, followed by ASCT, resulted in a significant and clinically meaningful PFS benefit, regardless of the maintenance therapy strategy. The present analysis of the GMMG-HD7 trial supports the MRD negativity benefit reported previously. The trial is ongoing and will evaluate the addition of Isa to lenalidomide during maintenance after a re-randomization (part 2).

Disclosures: Goldschmidt: GlycoMimetics Inc.: Research Funding; GlaxoSmithKline (GSK): Honoraria, Other: Support for attending meetings and/or travel, Research Funding; Heidelberg Pharma: Research Funding; Karyopharm: Research Funding; MorphoSys AG: Research Funding; Novartis: Honoraria, Other: Support for attending meetings and/or travel, Research Funding; Chugai: Honoraria, Other: Grants and/or provision of Investigational Medicinal Product; Celgene: Research Funding; Millennium Pharmaceuticals Inc.: Research Funding; Molecular Partners: Research Funding; Merck Sharp and Dohme (MSD): Research Funding; Takeda: Research Funding; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Grants and/or provision of Investigational Medicinal Product; support for attending meetings and/or travel, Research Funding; Array Biopharma/Pfizer: Other: Grants and/or provision of Investigational Medicinal Product; Pfizer: Honoraria, Other: Support for attending meetings and/or travel, Research Funding; Hoffmann-La Roche: Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Grants and/or provision of Investigational Medicinal Product; support for attending meetings and/or travel, Research Funding; Incyte Corporation: Research Funding; Bristol Myers Squibb/Celgene: Other: Grants and/or provision of Investigational Medicinal Product; Dietmar Hopp Foundation: Other: Grants and/or provision of Investigational Medicinal Product; Johns Hopkins University: Other: Grants and/or provision of Investigational Medicinal Product; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Research Funding; Adaptive Biotechnologies: Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel; grants and/or provision of Investigational Medicinal Product, Research Funding; Mundipharma GmbH: Other: Grants and/or provision of Investigational Medicinal Product. Fenk: BMS/Celgene: Honoraria, Other: travel accommodation and expenses; Amgen: Honoraria; GlaxoSmithKline (GSK): Other: travel expenses; Pfizer: Honoraria; Takeda: Honoraria; Janssen: Honoraria, Other: travel expenses; Sanofi: Honoraria. Besemer: AMGEN: Honoraria; GlaxoSmithKline: Honoraria; Pfizer: Honoraria; Janssen: Honoraria; Oncopeptides: Honoraria; Takeda: Honoraria. Schroers: GlaxoSmithKline: Honoraria, Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Takeda: Honoraria; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. von Metzler: Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; Stemline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline (GSK): Consultancy, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees. Hänel: Sobi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi-Aventis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; Gilead Sciences: Honoraria; Falk Foundation: Honoraria; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bayer Vital: Consultancy, Membership on an entity's Board of Directors or advisory committees; BristolMyersSquibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BristolMyersSquibb/Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees. Mann: Janssen: Consultancy; Sanofi: Consultancy; BristolMyersSquibb: Consultancy; Celgene: Consultancy. Leypoldt: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive: Honoraria; Abbvie: Honoraria, Research Funding; BMS/Celgene: Honoraria; Pfizer: Honoraria; Oncopeptides: Other: travel expenses; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Heilmeier: Sanofi-Aventis: Consultancy. Hundemer: BMS/Celgene: Other: travel expenses, Research Funding; BeiGene: Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Becton Dickinson: Membership on an entity's Board of Directors or advisory committees; Novartis: Research Funding; Janssen: Research Funding; Sanofi: Research Funding; Alexion: Research Funding; Roche: Research Funding. Holderried: Janssen: Other: travel expenses; Abbvie: Other: travel expenses; Otsuka Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Jazz Pharmaceuticals: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; GlaxoSmithKline (GSK): Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Astellas Pharma: Other: travel expenses; Neovii: Other: travel expenses; Immatics: Other: travel expenses; Sobi: Other: travel expenses. Trautmann-Grill: Amgen, Grifols, GSK, Novartis, Sanofi, SOBI: Consultancy; Amgen, Grifols, GSK, Novartis, Sanofi, SOBI, Takeda: Honoraria; Roche, Grifols: Speakers Bureau. Gezer: Takeda: Consultancy; Janssen/Cilag: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees. Klaiber-Hakimi: Incyte: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Beigen: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees. Mueller: Servier: Honoraria; Sanofi: Consultancy, Honoraria; MSD: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; GlaxoSmithKline (GSK): Consultancy; BMS: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Abbvie: Consultancy; Sobi: Honoraria. Shumilov: Takeda: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Gilead: Consultancy, Honoraria, Other: Travel and congress support; BMS: Consultancy, Honoraria; Incyte: Honoraria; Oncopeptides: Consultancy, Honoraria, Other: Travel and congress support; Stemline: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Other: Travel and congress support; Sanofi-Aventis: Consultancy, Honoraria, Other: Congress support. Knauf: Janssen: Consultancy, Honoraria; BMS/Celgene: Honoraria; BMS: Honoraria; Beigene: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Abbvie: Honoraria; Amgen: Honoraria; Sanofi: Honoraria. Michel: Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Other: travel expenses; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; GlaxoSmithKline (GSK): Honoraria, Other: travel expenses; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses. Lutz: BMS: Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees; Ipsen: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline (GSK): Membership on an entity's Board of Directors or advisory committees; EISAI: Membership on an entity's Board of Directors or advisory committees; Apogepha: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Pfizer: Speakers Bureau. Raab: Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria, Other: travel expenses; GSK: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Heidelberg Pharma: Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, Research Funding; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, Research Funding. Hoffmann: Janssen: Honoraria, Other: travel expenses; Sanofi-Aventis: Consultancy. Weisel: AbbVie: Other: Research grant to institution; Amgen: Consultancy, Honoraria, Other: Research grant to institution; Janssen: Consultancy, Honoraria, Other: Research grant to institution; GlaxoSmithKline: Consultancy, Honoraria, Other: Research grant to institution; Sanofi: Consultancy, Honoraria, Other: Research grant to institution; Adaptive Biotechnologies: Consultancy, Honoraria; Menarini: Consultancy, Honoraria; Novartis: Honoraria; AstraZeneca: Honoraria; BeiGene: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; Stemline: Honoraria; Roche Pharma: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb/Celgene: Consultancy, Honoraria, Other: Research grant to institution; Takeda: Consultancy, Honoraria; Regeneron: Consultancy. Salwender: Sanofi: Honoraria, Other: Travel grant; Stemline: Honoraria; Roche: Honoraria; Takeda: Honoraria; Pfizer: Honoraria; GlaxoSmithKline: Honoraria; Oncopeptides: Honoraria; Janssen: Honoraria, Other: Travel grant; Bristol Myers Squibb/Celgene: Honoraria, Other: Travel grant; Amgen: Honoraria, Other: Travel grant; AbbVie: Honoraria; Chugai: Honoraria; Sebia: Honoraria. Mai: GlaxoSmithKline (GSK): Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, Research Funding; Janssen-Cilag: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, Research Funding; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, Research Funding; Stemline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, Research Funding; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees.

OffLabel Disclosure: Isatuximab is not approved for upfront treatment in patients with newly-diagnosed multiple myeloma.

See more of: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma
See more of: Oral and Poster Abstracts

Previous Abstract | Next Abstract >>

^*signifies non-member of ASH

769 Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)